ES-002 is under clinical development by Elpiscience Biopharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ES-002’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ES-002 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ES-002 overview

ES-002 is under development for the treatment of advanced or metastatic solid tumors including pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal adenocarcinoma, gastric cancer. It acts by targeting CD39. The drug candidate is developed based on human-driven immune profiling technology that enables to measure the function and expression of target. It is administered through intravenous route.

Elpiscience Biopharma overview

Elpiscience Biopharma is a clinical-stage biotech company that develops immunotherapies to treat cancer patients. The company’s pipeline products include ES101, ES102, ES104, ES002, ES004, ES005, ES009, ES014, and ES028 antibody. It carries out immune-oncology therapies and approaches, and translational medicine. Elpiscience Biopharma’s products are used for the treatment of solid tumors, including colorectal, pancreatic, gastric cancer, cholangiocarcinoma, and non-small cell lung cancer, among others. The company carries out research and development activities through Immunoshine, AbLego, and Bispecific Macrophage Engager Antibody BiME platforms. It partners with biopharmaceutical companies and academic institutions to accelerate the development of potentially transformative cancer immunotherapies. Elpiscience Biopharma is headquartered in Shanghai, China.

Quick View ES-002 LOA Data

Report Segments
  • Innovator
Drug Name
  • ES-002
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.